Entities / Company
ImmunityBio.
biotech company
- Reports this week
- 0
- Active events
- 0
- Connections
- 36
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
Gone quiet
No new reports in 90+ days-
ImmunityBio presented Phase 3 clinical trial data, leading UBS to upgrade its rating from Neutral to Buy.Some support1 report
-
ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.Speculative1 report
-
ImmunityBio received prior approval in the U.S. on July 8, 2025, and Patrick Soon-Shiong was noted as Founder and Executive Chairman.Speculative1 report
-
ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.Some support1 report
-
ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.Some support2 reports
-
The FDA authorized an Expanded Access Program for ANKTIVA, the lead therapy of ImmunityBio, on July 31, 2025.Some support1 report
-
ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.Some support3 reports1 development inside
-
ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.Some support1 report
-
ImmunityBio's findings regarding GBM statistics were related to data provided by the American Brain Tumor Association.Some support1 report1 development inside
-
ImmunityBio announced a study originating from Culver City.Some support3 reports
-
The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around ImmunityBio this week
News at the entities that move ImmunityBio most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves ImmunityBio
-
SEC StructuralDHS, DOJ, and SEC formed a joint initiative to establish a Trade Fraud Task Force, setting standards for compliance.Moves ImmunityBio
-
United Arab Emirates StructuralUAE's first national rail service connects cities, establishing a new rail network between Fujairah and Abu Dhabi.Moves ImmunityBio
-
National Comprehensive Cancer Network OperationalThe American Cancer Society and National Comprehensive Cancer Network published findings in a journal regarding cancer in the United States.Moves ImmunityBio
-
Culver City Shared contextSeveral public figures exchanged views on the political climate and contributed to a benefit album project in Culver City.Moves ImmunityBio
-
UBS TransactionalThe Swiss parliament has proposed stricter capital requirements for UBS.Moves ImmunityBio
Connections
The 9 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Patrick Soon-Shiong Structural
Patrick Soon-Shiong serves as the Founder and Executive Chairman of ImmunityBio.
-
FDA Structural
ImmunityBio's existence and market viability are structurally dependent on the FDA's regulatory approvals and guidance.
-
SEC Structural
ImmunityBio operates under the oversight and filing requirements of the U.S. Securities and Exchange Commission (SEC).
-
United Arab Emirates Structural
The UAE granted regulatory approval for ImmunityBio's immunotherapy drug, enabling market access.
-
National Comprehensive Cancer Network Operational
ImmunityBio actively engages the National Comprehensive Cancer Network to seek guideline expansion and operates within its clinical context.
-
Culver City Shared context
ImmunityBio conducts studies and announces news while located in Culver City.
-
UBS Transactional
ImmunityBio presented Phase 3 clinical trial data to UBS.
-
Editas Medicine Operational
Both healthcare companies are actively competing for investment capital.
Show all 9 connections
-
Dunkirk Mentioned together
No evidence found linking ImmunityBio and Dunkirk in the provided timeline.
History
Events by the month they beganSeptember 2026
1 eventJuly 2026
1 eventJune 2026
12 events- Tariffs and onshoring trends are benefiting AI stocks, while a company acquisition enhances its liver disease portfolio, aided by a breakthrough designation.
- ImmunityBio presented Phase 3 clinical trial data, leading UBS to upgrade its rating from Neutral to Buy.
- ImmunityBio received Expanded Access authorization from the FDA on June 25, 2025.
- ImmunityBio received prior approval in the U.S. on July 8, 2025, and Patrick Soon-Shiong was noted as Founder and Executive Chairman.
- ImmunityBio initiated Phase 1 trials for NSCLC in US sites, while the FDA remained supportive of new data and the company sought guideline expansion from NCCN.
- ImmunityBio's offering requires filing with the SEC, with the associated book-running office located in Minneapolis.
- The FDA authorized an Expanded Access Program for ANKTIVA, the lead therapy of ImmunityBio, on July 31, 2025.
- ImmunityBio received FDA approval for its ANKTIVA immunotherapy drug on August 18, 2025, with treatment administered in Houston.
- ImmunityBio met with the FDA division on August 5, 2025, to present data regarding its ANKTIVA drug used in an NCI cancer prevention trial.
- ImmunityBio's findings regarding GBM statistics were related to data provided by the American Brain Tumor Association.
- ImmunityBio announced a study originating from Culver City.
- The FDA granted Expanded Access authorization for the Cancer BioShield™ platform of ImmunityBio on August 28, 2025. The company is now engaging with regulators to update clinical guidelines.